Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
Thank you for choosing ACROBiosystems. Would you rate our product and service？
Participate in the survey and you will have the chance to win the gift of your choice!
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| ILB-M5253 | Mouse | Mouse IL-2 R beta / CD122 Protein, Fc Tag |  |
|
|
| ILA-C52H5 | Canine | Canine IL-2 R beta Protein, His Tag |  |
|
|
| ILA-M52H5 | Mouse | Mouse IL-2 R beta Protein, His Tag |  |
|
|
| ILB-H82E3 | Human | Biotinylated Human IL-2 R beta / CD122 Protein, His,Avitag™ |  |
|
|
| ILB-H5253 | Human | Human IL-2 R beta / CD122 Protein, Fc Tag (MALS & SPR verified) |  |
|
|
| CD2-H5221 | Human | Human IL-2 R beta / CD122 Protein, His Tag (SPR verified) |  |
|
|
Human IL-2 R beta, Fc Tag (Cat. No. ILB-H5253) captured on CM5 chip via anti-human IgG Fc antibody can bind IL-2, Tag Free (Cat. No. IL2-H4113) with an affinity constant of 0.473 μM as determined in a SPR assay (Biacore T200) (QC tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Basiliximab | CHT-25; chRFT5; CHI-621; SDZ-CHI-621 | Approved | Novartis Pharma Ag | 舒莱, Simulect | Japan | Rejection of organ transplantation | Novartis Pharma Ag | 1998-05-12 | Rejection of renal transplantation; Rejection of organ transplantation; Colitis, Ulcerative; Uveitis | Details |
| Recombinant Human Interleukin-2(Ⅰ) (Liaoning Satellite Biological Products) | Approved | Liaoning Satellite Biological Products Research Institute (Limited) | Mainland China | Neoplasms | Liaoning Satellite Biological Products Research Institute (Limited) | 2002-02-04 | Neoplasms | Details | ||
| Daclizumab | R-35; BIIB-019; RO-247375 | Approved | Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd | Zinbryta, Zenapax | United States | Multiple Sclerosis | Biogen Inc | 1997-12-10 | Multiple Sclerosis, Relapsing-Remitting; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Multiple Sclerosis; Rejection of organ transplantation; Asthma; Colitis, Ulcerative | Details |
| Denileukin diftitox | E-7272; E-7777; DAB-389; LY-335348; DAB389IL-2 | Approved | Eisai Co Ltd | Ontak, Onzar | United States | Lymphoma, T-Cell, Cutaneous | Eisai Inc | 1999-02-05 | Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell; Leukemia; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma | Details |
| Daclizumab biosimilar (Shanghai CP Guojian) | Approved | Shanghai Cp Guojian Pharmaceutical Co Ltd | 健尼哌 | Mainland China | Rejection of renal transplantation | null | 2011-01-12 | Rejection of renal transplantation | Details | |
| Basiliximab | CHT-25; chRFT5; CHI-621; SDZ-CHI-621 | Approved | Novartis Pharma Ag | 舒莱, Simulect | Japan | Rejection of organ transplantation | Novartis Pharma Ag | 1998-05-12 | Rejection of renal transplantation; Rejection of organ transplantation; Colitis, Ulcerative; Uveitis | Details |
| Recombinant Human Interleukin-2(Ⅰ) (Liaoning Satellite Biological Products) | Approved | Liaoning Satellite Biological Products Research Institute (Limited) | Mainland China | Neoplasms | Liaoning Satellite Biological Products Research Institute (Limited) | 2002-02-04 | Neoplasms | Details | ||
| Daclizumab | R-35; BIIB-019; RO-247375 | Approved | Abbvie Inc, Biogen Inc, F. Hoffmann-La Roche Ltd | Zinbryta, Zenapax | United States | Multiple Sclerosis | Biogen Inc | 1997-12-10 | Multiple Sclerosis, Relapsing-Remitting; Gastrointestinal Diseases; Inflammatory Bowel Diseases; Multiple Sclerosis; Rejection of organ transplantation; Asthma; Colitis, Ulcerative | Details |
| Denileukin diftitox | E-7272; E-7777; DAB-389; LY-335348; DAB389IL-2 | Approved | Eisai Co Ltd | Ontak, Onzar | United States | Lymphoma, T-Cell, Cutaneous | Eisai Inc | 1999-02-05 | Lymphoma, T-Cell, Peripheral; Lymphoma, B-Cell; Leukemia; Lymphoma, T-Cell, Cutaneous; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma | Details |
| Daclizumab biosimilar (Shanghai CP Guojian) | Approved | Shanghai Cp Guojian Pharmaceutical Co Ltd | 健尼哌 | Mainland China | Rejection of renal transplantation | null | 2011-01-12 | Rejection of renal transplantation | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Inolimomab | B-B10; BT-563; MAb-BT-563 | Phase 3 Clinical | Eusa Pharma, Jazz Pharmaceuticals | Graft vs Host Disease | Details |
| Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 | HuMikβ1-1 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd, National Institutes Of Health | Leukemia, Lymphoid | Details |
| Basiliximab biobetter (Mabtech/Sorrento) | STI-003 | Phase 3 Clinical | Taizhou Maibo Taike Biotechnology Co Ltd | Autoimmune Diseases | Details |
| ANV-419 | Phase 2 Clinical | Anaveon AG | Solid tumours | Details | |
| Camidanlumab tesirine | ADCT-301 | Phase 2 Clinical | Genmab, Adc Therapeutics | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Hodgkin Disease; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms | Details |
| Inolimomab | B-B10; BT-563; MAb-BT-563 | Phase 3 Clinical | Eusa Pharma, Jazz Pharmaceuticals | Graft vs Host Disease | Details |
| Anti-interleukin-2 receptor monoclonal antibody Mikbeta1 | HuMikβ1-1 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd, National Institutes Of Health | Leukemia, Lymphoid | Details |
| Basiliximab biobetter (Mabtech/Sorrento) | STI-003 | Phase 3 Clinical | Taizhou Maibo Taike Biotechnology Co Ltd | Autoimmune Diseases | Details |
| ANV-419 | Phase 2 Clinical | Anaveon AG | Solid tumours | Details | |
| Camidanlumab tesirine | ADCT-301 | Phase 2 Clinical | Genmab, Adc Therapeutics | Pancreatic Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Lymphoma, Non-Hodgkin; Fallopian Tube Neoplasms; Leukemia, Myeloid, Acute; Colorectal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Urinary Bladder Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Hodgkin Disease; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Esophageal Neoplasms; Carcinoma, Renal Cell; Ovarian Neoplasms | Details |
This web search service is supported by Google Inc.
A-Z